Palvella Therapeutics, Inc. (PVLA)

Palvella Therapeutics, Inc. is trading at $150.48, down 1.98% on the session. The 50 day average sits at $135.54 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 57.3, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $137.37 with resistance near $158.08, so that band frames the current range. Average daily movement is roughly $9.30, or about 6.2% of the share price, which is what any stop placement has to allow for. The overall health score of 60 out of 100 combines a trend score of 75, momentum of 82 and a risk score of 6.

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.